| 0.7857 0.006 (0.73%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.01 | 1-year : | 1.18 |
| Resists | First : | 0.87 | Second : | 1.01 |
| Pivot price | 0.75  |
|||
| Supports | First : | 0.72 | Second : | 0.63 |
| MAs | MA(5) : | 0.76 |
MA(20) : | 0.75 |
| MA(100) : | 0.92  |
MA(250) : | 1.05 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 47.3 |
D(3) : | 42.6 |
| RSI | RSI(14): 54.2 |
|||
| 52-week | High : | 1.42 | Low : | 0.63 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ QNCX ] has closed below upper band by 32.0%. Bollinger Bands are 21.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.8 - 0.8 | 0.8 - 0.8 |
| Low: | 0.75 - 0.75 | 0.75 - 0.75 |
| Close: | 0.78 - 0.79 | 0.79 - 0.79 |
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Tue, 25 Jun 2024
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia - Business Wire
Mon, 03 Jun 2024
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System - Business Wire
Mon, 13 May 2024
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results - Business Wire
Mon, 01 Apr 2024
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results - Business Wire
Thu, 22 Feb 2024
Quince Therapeutics Launches Scientific Advisory Board - Business Wire
Mon, 23 Oct 2023
Quince Therapeutics Completes Acquisition of EryDel S.p.A. - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 13.1 (%) |
| Held by Institutions | 27.7 (%) |
| Shares Short | 2,360 (K) |
| Shares Short P.Month | 2,050 (K) |
| EPS | -0.76 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.72 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -13 % |
| Return on Equity (ttm) | -36.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -1.04 |
| PEG Ratio | 0 |
| Price to Book value | 0.45 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.48 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|